Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Biomark X

Fluidigm has launched BioMark X, the latest generation of its Biomark microfluidic real-time PCR platform. Biomark X integrates the company's Juno microfluidic sample preparation platform with the company's current BioMark HD instrument into a single sample-to-answer platform, the company said. The integrated system can be used for a variety of applications including genotyping, sample ID, strain ID, conservation biology, personal genomics, gene expression, pathogen detection, pharmacogenomics assays, and transplant prognostics, according to Fluidigm. The platform also supports development and creation of custom assays, and the ability to scale the number of targets based on need. According to the company's website, BioMark X supports the company's 48.48 Dynamic Array Integrated Fluidic Circuit (IFC), enabling 2,304 reactions using 48 samples and assays; and the 96.96 Dynamic Array IFC, enabling 9,216 reactions using 96 samples and assays.

Fluidigm said the platform is in a phased launch with deliveries expected to commence in the first quarter of 2022.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.